In the news
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Takara Bio Europe AB to launch Cellartis iPS Cell to Hepatocyte Differentiation System
Date: November 16, 2015
Categories: Press release
Göteborg, Sweden, November 16, 2015, Takara Bio Europe AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching the Cellartis iPS Cell to Hepatocyte Differentiation System and related ancillary products. This system provides a complete solution for directed differentiation of disease-specific or patient-specific human inducible pluripotent stem (hiPS) cells to hepatocytes by combining a standardized protocol and optimized, ready-to-use media and coating reagents.
Takara Bio Europe releases an innovative iPS cell culture medium for pre-clinical use: Cellartis DEF-CS Xeno-Free Culture Medium
Date: June 1, 2015
Categories: Press release
Göteborg, Sweden, June 1, 2015, Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture system for iPS cell culture. This chemically-defined culture system is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.
Clontech Laboratories, Inc. signs agreement with Ludwig Cancer Research for access to Smart-seq2
Date: March 23, 2015
Categories: Press release
Mountain View, CA—March 23, 2015—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has entered into an exclusive agreement with Ludwig Cancer Research for rights to the Smart-seq2 method for single-cell RNA-seq, which was developed in Rickard Sandberg’s laboratory at Ludwig Stockholm. As a result of this agreement, Clontech will become the exclusive supplier of SMART-Seq2 technology.
Clontech Laboratories, Inc. licenses CRISPR/Cas9 technology from the Broad Institute
Date: October 27, 2014
Categories: Press release
Mountain View, CA—October 27, 2014—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that they have entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Clontech Laboratories, Inc. releases the DNA SMART ChIP-Seq Kit
Date: September 22, 2014
Categories: Press release
Mountain View, CA—September 22, 2014—Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the DNA SMART ChIP-Seq Kit. This kit adapts Clontech's patented SMART technology in an innovative manner for use with low-input samples, including both dsDNA and ssDNA templates, to generate ChIP-seq libraries for NGS.
Announcement—Clontech Laboratories, Inc. partners with Flash Therapeutics SAS to provide highly concentrated purified lentiviral particles
Date: May 5, 2014
Categories: Press release
Mountain View, CA—May 5, 2014—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Flash Therapeutics SAS to combine Clontech's Living Colors fluorescent protein and Tet-On 3G technologies with Flash Therapeutics' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery.
Announcement—Clontech Laboratories, Inc. releases the SMARTer Stranded RNA-Seq Kit
Date: October 21, 2013
Categories: Press release
Mountain View, CA—October 21, 2013—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the SMARTer Stranded RNA-Seq Kit for strand-specific RNA-Seq from low-input RNA samples. This kit integrates Illumina library preparation with SMART cDNA amplification to create indexed libraries in less than four hours and provides high-quality stranded data, with greater than 99% accuracy in strand identification.
Clinical-grade RetroNectin reagent available to support gene therapy clinical research
Date: June 17, 2013
Categories: Press release
June 17, 2013—Mountain View, CA—In an effort to aid progress in gene therapy clinical research, representatives of Clontech Laboratories, Inc., and its parent company Takara Bio Inc. announce the availability of clinical-grade RetroNectin reagent for direct supply to biomedical researchers. RetroNectin reagent is designed to enable efficient retroviral transduction of genes into hematopoietic stem cells as well as lymphocytes and other blood cells.
Clontech Laboratories, Inc., partners with Rubicon Genomics, Inc., to increase speed and efficiency of sample preparation for RNA sequencing
Date: June 6, 2013
Categories: Press release
Mountain View, CA and Ann Arbor, MI—June 6, 2013—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and Rubicon Genomics, Inc., announced today that they have partnered to integrate Clontech's SMART technology with Rubicon's ThruPLEX technology to increase the efficiency and quality of RNA sample preparation for a variety of next-generation sequencing (NGS) applications. The launch of the SMARTer Universal Low Input RNA Library Prep Kit, which combines ThruPLEX technology with Clontech's SMARTer Universal Low Input RNA Kit for Sequencing, provides an unparalleled solution to generate libraries for transcriptome analysis from very low amounts of total RNA, including compromised or non-polyA RNA samples.
Announcement—Clontech Laboratories, Inc., releases the SMARTer Universal Low Input RNA Kit for Sequencing
Date: May 1, 2013
Categories: Press release
Mountain View, CA—May 1, 2013—Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the release of the SMARTer Universal Low Input RNA Kit for Sequencing. The SMARTer Universal Low Input RNA Kit extends Clontech's NGS (next-generation sequencing) solutions to include low input samples of compromised RNA.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2024 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
